Eric K. Steffe
1100 New York Ave, NW Suite 600
Washington, DC 20005
Eric Steffe is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group. He also serves as the chair of the firm’s Patent Prosecution Practice. Eric’s practice involves providing strategic counsel to his clients in various areas of patent law, with special emphasis on therapeutic antibodies, gene therapies, CRISPR, vaccines, diagnostics, antisense technologies, personalized medicine, and cell culturing/bioprocessing methods.
Eric has extensive expertise in inter partes review proceedings, patent reexaminations, managing complicated multi-family patent portfolios protecting pipeline and FDA-approved biotech products, preserving freedom to operate, interferences, and the IP issues arising out of industry collaborations and ongoing research. Additionally, his practice includes providing strategic advice to numerous companies seeking to launch products. Eric has published and lectured extensively in the field, testified before Congress as a legal expert regarding the Cooperative Research and Technology Enhancement (CREATE) Act.
Since 2017, The Legal 500 recognized Eric as a "Leading Lawyer" in the U.S. for his patent prosecution work; a distinction awarded to only ten other attorneys in the entire country. He was awarded the LMG Life Sciences, "Patent Strategy & Management Attorney of the Year - District of Columbia" in 2018 and has been an LMG Life Sciences Star since 2017. Further recognition in 2017 includes being named an IAM Patent 1000 leading practitioner for patent prosecution and a ranking in the Who’s Who Legal guide for patents. Additionally, Eric's presence in The Legal 500 as a “Leading Lawyer in Intellectual Property – Patent Prosecution: Utility and Design Patents” has been concurrent since 2015.
Eric received his J.D. from George Mason University School of Law, his M.S. in molecular genetics, and his B.S. in physics from the University of Georgia.